Litcius/Paper detail

Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial

Sean Wharton, Paula Freitas, Jøran Hjelmesæth, Maria Kabisch, Kristian Kandler, Ildiko Lingvay, Maria Quiroga, Julio Rosenstock, W. Timothy Garvey

2025The Lancet Diabetes & Endocrinology62 citationsDOI

Topics & Concepts

MedicineSemaglutideObesityInternal medicineGermanMEDLINEEndocrinologyDiabetes mellitusClinical trialPhase (matter)Weight lossPediatricsBody weightPhysical therapyObesity SurgeryDiabetes Treatment and ManagementBariatric Surgery and OutcomesMetabolism, Diabetes, and Cancer
Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial | Litcius